PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges.

Sachpekidis, Christos; Alberts, Ian; Rominger, Axel; Afshar-Oromieh, Ali (2019). PSMA radioligand therapy in prostate cancer: overview, latest advances and remaining challenges. Immunotherapy, 11(15), pp. 1267-1271. Future Medicine Ltd 10.2217/imt-2019-0146

[img] Text
Sachpekidis-2019-Immunotherapy_PSMA radioligand therapy in prostate Cancer.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (664kB) | Request a copy

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Clinic of Nuclear Medicine

UniBE Contributor:

Sachpekidis, Christos; Alberts, Ian Leigh; Rominger, Axel Oliver and Afshar Oromieh, Ali

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1750-7448

Publisher:

Future Medicine Ltd

Language:

English

Submitter:

Sabine Lanz

Date Deposited:

23 Jan 2020 14:28

Last Modified:

23 Jan 2020 14:28

Publisher DOI:

10.2217/imt-2019-0146

PubMed ID:

31496329

Uncontrolled Keywords:

actinium-225 (225Ac) lutetium-177 (177Lu) metastatic castration-resistant prostate cancer (mCRPC) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT)

BORIS DOI:

10.7892/boris.137420

URI:

https://boris.unibe.ch/id/eprint/137420

Actions (login required)

Edit item Edit item
Provide Feedback